Acromegaly and COVID-19, Lessons, and New Opportunities

Overview

Journal Pituitary

Specialty Endocrinology

Date 2024 May 31

PMID 38819618

Authors

Elena V Varlamov

Maria Fleseriu

Affiliations

Soon will be listed here.

Abstract

The COVID-19 pandemic created challenges in effective management of patients with acromegaly. Specifically, with regards to timely diagnosis, delays in surgeries, and disruption(s) to routine patient care. A transition to telemedicine did help to overcome safety restrictions that were placed on in-person care. Creation of surgical safety protocols in conjunction with widespread testing for COVID-19 has also helped with the resumption of pituitary surgery cases. However, acromegaly related comorbidities including cardiovascular disease, diabetes mellitus, sleep apnea and respiratory disease, vertebral fractures, and hypopituitarism, may increase the risk of a more severe COVID-19 infection course. Of note and to date, no negative trends in COVID-19 related outcomes have been reported in patients with acromegaly. Nevertheless, anxiety and depression rates in patients with acromegaly are higher than those in the general population. More studies are needed to assess the true impact of the COVID-19 pandemic on morbidity, mortality, and neuropsychiatric health of patients with acromegaly.

References

Fleseriu M, Langlois F, Lim D, Varlamov E, Melmed S . Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022; 10(11):804-826. DOI: 10.1016/S2213-8587(22)00244-3. View

Gadelha M, Kasuki L, Lim D, Fleseriu M . Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. Endocr Rev. 2018; 40(1):268-332. DOI: 10.1210/er.2018-00115. View

Fleseriu M, Barkan A, Del Pilar Schneider M, Darhi Y, de Pierrefeu A, Ribeiro-Oliveira Jr A . Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States. Pituitary. 2022; 25(2):296-307. PMC: 8894179. DOI: 10.1007/s11102-021-01198-5. View

Giustina A, Biermasz N, Casanueva F, Fleseriu M, Mortini P, Strasburger C . Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2023; 27(1):7-22. PMC: 10837217. DOI: 10.1007/s11102-023-01360-1. View

Melmed S, Kaiser U, Lopes M, Bertherat J, Syro L, Raverot G . Clinical Biology of the Pituitary Adenoma. Endocr Rev. 2022; 43(6):1003-1037. PMC: 9695123. DOI: 10.1210/endrev/bnac010. View

Yedinak C, Hameed N, Gassner M, Brzana J, McCartney S, Fleseriu M . Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study. Pituitary. 2015; 18(5):701-9. DOI: 10.1007/s11102-015-0643-8. View

Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B . Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020; 21(4):667-678. PMC: 7942783. DOI: 10.1007/s11154-020-09588-z. View

Fleseriu M, Buchfelder M, Cetas J, Fazeli P, Mallea-Gil S, Gurnell M . Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective. Pituitary. 2020; 23(4):327-337. PMC: 7300368. DOI: 10.1007/s11102-020-01059-7. View

Fleseriu M, Dekkers O, Karavitaki N . Endocrinology in the time of COVID-19: Management of pituitary tumours. Eur J Endocrinol. 2020; 183(1):G17-G23. PMC: 7938006. DOI: 10.1530/EJE-20-0473. View

10.

Meyerowitz E, Scott J, Richterman A, Male V, Cevik M . Clinical course and management of COVID-19 in the era of widespread population immunity. Nat Rev Microbiol. 2023; 22(2):75-88. DOI: 10.1038/s41579-023-01001-1. View

11.

Tenforde M, Link-Gelles R . Reduction in COVID-19-related mortality over time but disparities across population subgroups. Lancet Public Health. 2023; 8(5):e327-e328. PMC: 10188114. DOI: 10.1016/S2468-2667(23)00078-6. View

12.

Omboni S, Padwal R, Alessa T, Benczur B, Green B, Hubbard I . The worldwide impact of telemedicine during COVID-19: current evidence and recommendations for the future. Connect Health. 2022; 1:7-35. PMC: 7612439. DOI: 10.20517/ch.2021.03. View

13.

Crisafulli S, Luxi N, Sultana J, Fontana A, Spagnolo F, Giuffrida G . Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol. 2021; 185(2):251-263. DOI: 10.1530/EJE-21-0216. View

14.

Gatto F, Khorrami K, Nista F, Corica G, Ferone D . Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge. Endocr Pract. 2021; 27(8):856-857. PMC: 8139170. DOI: 10.1016/j.eprac.2021.05.005. View

15.

Demir A, Sulu C, Kara Z, Sahin S, Ozaydin D, Sonmez O . Changing presentation of acromegaly in half a century: a single-center experience. Pituitary. 2023; 26(5):573-582. DOI: 10.1007/s11102-023-01344-1. View

16.

Esposito D, Ragnarsson O, Johannsson G, Olsson D . Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020; 182(6):523-531. DOI: 10.1530/EJE-20-0019. View

17.

Siegel S, Streetz-van der Werf C, Schott J, Nolte K, Karges W, Kreitschmann-Andermahr I . Diagnostic delay is associated with psychosocial impairment in acromegaly. Pituitary. 2012; 16(4):507-14. DOI: 10.1007/s11102-012-0447-z. View

18.

Fleseriu M, Biller B, Freda P, Gadelha M, Giustina A, Katznelson L . A Pituitary Society update to acromegaly management guidelines. Pituitary. 2020; 24(1):1-13. PMC: 7864830. DOI: 10.1007/s11102-020-01091-7. View

19.

Giustina A, Legg E, Cesana B, Frara S, Mortini P, Fleseriu M . Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era. Endocrine. 2021; 71(2):273-280. PMC: 7790473. DOI: 10.1007/s12020-020-02565-1. View

20.

Williams S, Leong S . One year into the COVID-19 pandemic: What do we know so far from studies assessing risk and mitigation of droplet aerosolisation during endonasal surgery? A systematic review. Clin Otolaryngol. 2021; 46(6):1368-1378. PMC: 8653184. DOI: 10.1111/coa.13854. View